Trial Profile
Phase II Study of High-Dose Rituximab Combined With Temozolomide as Treatment for Patients With Primary CNS Lymphoma
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Rituximab (Primary) ; Temozolomide
- Indications B-cell lymphoma; CNS cancer
- Focus Therapeutic Use
- 22 Feb 2016 Status changed from recruiting to discontinued, according to ClinicalTrials.gov record.
- 01 Jul 2015 Planned End Date changed from 1 May 2017 to 1 May 2016 as reported by ClinicalTrials.gov record.
- 21 Jul 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.